Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked. Bodor, J., Patel, J. D., Ross, E. A., Litwin, S., Clapper, M., Levy, B., Wakelee, H. A., Borghaei, H., Treat, J. LIPPINCOTT WILLIAMS & WILKINS. 2020
View details for Web of Science ID 000560368309251